According to Taysha Gene Therapies's latest financial reports the company has $0.14 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $87.88 M | -41.06% |
2021-12-31 | $0.14 B | -40.66% |
2020-12-31 | $0.25 B | |
2019-12-31 | $N/A |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | $0.20 B | 44.63% | ๐บ๐ธ USA |